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Aims The aim of this study was to investigate in patients with stable angina the effects on costs of frontline diagnostics by
exercise-stress testing (ex-test) vs. coronary computed tomography angiography (CTA).
Methods
and results
In two coronary units at Lillebaelt Hospital, Denmark, 498 patients were identified in whom either ex-test (n ¼ 247)
or CTA (n ¼ 251) were applied as the frontline diagnostic strategy in symptomatic patients with a low-intermediate
pre-test probability of coronary artery disease (CAD). During 12 months of follow-up, death, myocardial infarction
and costs associated with downstream diagnostic utilization (DTU), treatment, ambulatory visits, and hospitalizations
were registered. There was no difference between cohorts in demographic characteristics or the pre-test probability
of significant CAD. The mean (SD) age was 56 (11) years; 52% were men; and 96% were at low-intermediate pre-test
probability of CAD. All serious cardiac events (n ¼ 3) during follow-up occurred in patients with a negative ex-test
result. Mean costs per patient associated with DTU, ambulatory visits, and cardiovascular medication were significant-
ly higher in the ex-test than in the CTA group. The mean (SD) total costs per patient at the end of the
follow-up were 14% lower in the CTA group than in the ex-test group, E 1510 (3474) vs. E1777 (3746) (P ¼ 0.03).
Conclusion Diagnostic assessment of symptomatic patients with a low-intermediate probability of CAD by CTA incurred lower
costs when compared with the ex-test. These findings need confirmation in future prospective trials.
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Introduction
In the European Union countries, coronary artery disease (CAD) is
responsible for .600.000 deaths every year.1 The associated
annual costs have been estimated at E49 billion, which is equiva-
lent to 2.5% of the EU’s total health expenditures.2 Therefore,
the economic efficiency of cardiac diagnostic strategies is gaining
increasing attention. For decades, ischaemia testing including
exercise-stress testing (ex-test) has been recommended as the
diagnostic gatekeeper in patients suspected of CAD.3 In line with
a tremendous evolution in computed tomography technology,
non-invasive coronary computed tomography angiography (CTA)
has emerged as a diagnostic alternative to conventional ischaemia
testing in patients with a low to intermediate pre-test probability
of CAD.4 However, the use of CTA as a frontline diagnostic test
in patients suspected of CAD has been questioned since CTA
identifies more patients with atherosclerosis than conventional
functional diagnostic methods, hence add the risk of introducing
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further unnecessary diagnostic and therapeutic procedures.5
Therefore, the purpose of this study was to evaluate the effects
on costs of a real-world frontline diagnostic strategy using either
the ex-test or CTA in patients with stable angina and a
low-to-intermediate pre-test likelihood of disease.
Methods
Patients
Between January 2007 and February 2008, 1267 patients without
known CAD consecutively referred (by general practitioners or non-
cardiology ambulatory clinics) for the evaluation of chest pain at the
ambulatory clinics at two coronary units (Vejle and Fredericia, loca-
lized 30 km apart) at Lillebaelt Hospital, Denmark were retrospectively
evaluated for inclusion in this study. Patients were referred to either of
the two units based on strictly geographical considerations. Patients
underwent an initial clinical evaluation by an experienced cardiovascu-
lar clinician. Until 2007 the preferred frontline diagnostic method at Lil-
lebaelt Hospital for patients suspected of angina with a low to
intermediate pre-test probability of CAD was the ex-test. In January
2007 the Vejle unit implemented CTA as the preferred frontline diag-
nostic test in such patients. The change in diagnostic strategy in only
one of the Lillebaelt Hospital coronary units allowed us to compare
the impact on costs of the two diagnostic strategies. High-risk patients
at both units preferably were referred for invasive coronary angiog-
raphy (ICA), whereas patients with a low or intermediate pre-test
probability of CAD in whom the ex-test or CTA could not be per-
formed (e.g. physical incapacity or renal insufficiency) preferably
were referred for myocardial perfusion scintigraphy imaging (MPI) or
ICA. There was no difference in the competence level or professional
charge of the referring clinicians at the two units. After the initial clin-
ical evaluation, 260 patients were discharged or referred for diagnostic
evaluation of non-cardiac disease, 363 (Fredericia unit, n ¼ 164; Vejle
unit, n ¼ 199) patients were referred for ICA, and 146 (Fredericia,
n ¼ 89; Vejle, n ¼ 57) patients to MPI. Thus, 498 patients with sus-
pected CAD were referred for either an initial ex-test (n ¼ 247) or
CTA (n ¼ 251).
The index diagnostic test date was defined as the date a patient
underwent either of the two tests. Baseline demographics and patients’
medical records were registered from electronic patient files. Patients
were classified as having a low (,13.4%), intermediate, or high
(.87.2%) pre-test probability of CAD according to the original
Diamond–Forrester algorithm6. Symptoms were categorized as non-
anginal, atypical, or typical angina.7
The study was approved by the Danish Data Protection Agency
(Journal Number, 2009-413523) with a waiver for individual informed
consent by the Regional Ethical Committee.
Exercise-stress testing
The ex-test was performed using a national standardized protocol.8 In
the latter protocol, cessation of beta-blockers is recommended prior
to an ex-test. The test was considered positive in the presence of
≥0.1 mV horizontal or descending ST depression measured 80 ms
from the J-point, ventricular arrhythmia during or after exercise, a sys-
tolic blood pressure drop ≥20 mmHg during exercise, or if the patient
developed angina pectoris. The test was considered inconclusive in the
absence of the above-mentioned criteria without reaching 85% of the
age-adjusted target heart rate. The ex-tests were performed by physi-
cians with knowledge of all relevant patient information. Before test




A standard protocol for image acquisition at a 64-slice Dual Source CT
system (Siemens Definition, Siemens Medical Solution, Forcheim,
Germany) was applied.9 Contraindications to CTA were pregnancy,
renal insufficiency, or known allergy to iodinated contrast. Assessment
of CTA was performed using axial source images and multi-planar
reconstructions. The CTA result was defined as positive in the pres-
ence of at least one atherosclerotic lesion causing ≥50% luminal nar-
rowing and negative in the absence of a significant coronary artery
lesion. The CTA evaluation and conclusions were made by cardiolo-
gists with knowledge of all relevant patient information. Extra-cardiac
analysis was performed in all patients by experienced radiologists.
Post-test management of patients
All test results were reviewed by experienced cardiac clinicians before
post-test management. Post-test management of patients were at the
discretion of the referring clinicians, however, according to internal
guidelines at the department of cardiology, Lillebaelt Hospital during
the study period, ICA was recommended in symptomatic patients
with a positive index test result, whereas no further testing was recom-
mended in those with a normal test result. Patients with an equivocal
index test result were managed at the discretion of the referring phys-
ician. Patients with extra-cardiac findings were managed at the discre-
tion of the reading CTA physician after reviewing the case with other
specialists.
Follow-up
Patients were followed for 12 months after the index test. The occur-
rence of major adverse events including cardiac death and non-fatal
myocardial infarction International Statistical Classification of Diseases
and Related Health Problems, 10th Revision [ICD-10] codes D121,
DI210, DI210B, DI219, DI252 were registered during the follow-up.
In addition, data on cardiac downstream test utilization, cardiovascular
medication, coronary revascularization (percutaneous coronary inter-
vention, coronary bypass graft surgery), and hospitalizations for un-
stable angina (ICD-10 codes DI200, DI200B+C) or stable angina
(ICD-10 codes DI201, DI208-9, DI251, DI251B+C), hospitalizations
on suspicion of CAD (ICD-10 codes DR079, DZ034), and ambulatory
visits on a suspicion of CAD (ICD-10 codes DI200, DI200B+C, DI201,
DI208-9, DI251, DI251B+C, DR079, DZ034), respectively, together
with data (DTU and treatment) associated with extra-cardiac findings
during the follow-up period were registered. Data were derived from
the Danish National Patient Registry, the West-Danish Heart Registry,
and the University of Southern Denmark Pharmacoepidemiological
Database.
Radiation dose
The dose-length product (DLP) of CTA was derived from patient files.
The effective radiation dose was derived as the product of DLP and an
organ weighting factor (0.014) for the chest in adults.10 Information on
the radiation dose related to ICA and MPI was obtained from patient
files and the West-Danish Heart Registry.
Statistical analysis
Continuous variables are expressed as means (standard deviations, SD)
and medians (ranges) as appropriate. Continuous variables were com-
pared using Student’s t-test (for normally distributed variables) or the
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Mann–Whitney U test (for variables not normally distributed). All
costs were expressed in 2007 Euros (EUR). Cost estimations were
based on diagnosis-related group charges, charges for outpatient con-
tacts, and pharmacy retail prices. Total costs were calculated as the
sum of cardiac DTU, cardiovascular medication, coronary revasculari-
zations, hospitalizations, and costs associated with ambulatory consul-
tations during follow-up. A secondary analysis including costs
associated with extra-cardiac findings (DTU and treatment) was per-
formed. The cumulative total costs were computed at 1, 6, and 12
months after the index diagnostic test. Comparison of cost data in
the ex-test and CTA groups were performed adjusting for the
pre-test probability of CAD and the index test result (positive vs.
negative), respectively. Regression analysis was performed in order
to adjust cost estimates from differences in the pre-test probability
of CAD and other baseline covariates. A substantial number of patients
incurred no downstream costs and therefore a two-part model was
applied.11 In this analysis the probability that the patient had zero or
non-zero costs is predicted in the first part. First logistic regression
analysis was applied in order to estimate the probability that the
patient had zero or non-zero costs. In the second part of the model,
the level of cost conditional upon having positive costs was predicted.
We applied a generalized linear regression model (GLM), applying a log
link function and assuming an inverse Gaussian distribution. Besides the
test dummy variable ‘ex-test yes/no’ covariates in the GLM included
the pre-test probability of CAD. The estimated costs are derived by
multiplying the predictions from the two components (part 1 and 2)
together. Cost analyses were performed using SAS (SAS Institute,
Inc., Cary, NC, USA) software; otherwise the SPSS version 17.0
(SPSS, Chicago, USA) was applied. A significance level of 0.05 (two-
sided) was considered statistically significant.
Results
Information on baseline demographics, pre-test probability of
CAD, and medications are presented in Table 1. No differences
between the ex-test and the CTA groups could be detected
except for more use of nitrates in the ex-test compared with
the CTA group. The proportion of patients with a positive test
result was higher in the ex-test group than in the CTA group, 26
vs. 12% (P, 0.001). A negative test result was more frequent in
the CTA compared with the ex-test group, 76 vs. 66% (P ¼
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






Age (years) (mean+ SD) 56+12 55+11 0.92
Male, n (%) 132 (54) 123 (49) 0.32
Risk factors for CAD
Hypertension, n (%) 131 (53) 149 (59) 0.16
Hypercholesterolaemia,
n (%)
208 (84) 203 (81) 0.33
Diabetes mellitus, n (%) 24 (10) 21 (8) 0.60
Current smoking, n (%) 110 (45) 128 (51) 0.15
Symptoms
Typical angina, n (%) 14 (6) 14 (6) 0.97
Atypical angina, n (%) 54 (22) 47 (19) 0.38
Non-anginal chest pain, n (%) 179 (73) 190 (76) 0.40
Pre-test likelihood of CAD
Low, n (%) 68 (28) 68 (27) 0.93
Intermediate, n (%) 171 (69) 173 (69) 0.79
High, n (%) 8 (3) 10 (4) 0.66
Mean+ SD 27+23 26+23 0.35
Anti-platelet agents, n (%) 86 (35) 87 (35) 0.97
b-Blockers, n (%) 64 (26) 67 (27) 0.84
Angiotensin-converting
enzyme inhibitors, n (%)
39 (16) 42 (17) 0.78
Calcium receptor blockers, n
(%)
47 (19) 33 (13) 0.07
Angiotensin 2 receptor
blockers, n (%)
13 (5) 13 (5) 0.97
Statins, n (%) 64 (26) 71 (28) 0.55
Nitrates, n (%) 54 (22) 28 (11) 0.001
Any anti-anginal medication,
n (%)
116 (47) 100 (40) 0.16
b-Blockers, beta receptor blockers; ex-test, exercise-stress testing; CTA, coronary
computed tomography angiography; CAD, coronary artery disease; SD, standard
deviation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .











22 (9) 10 (4) 0.03
Invasive coronary
angiography








12 (5) 15 (6) 0.60
Cardiovascular medication
Anti-platelet agents 37 (15) 22 (9) 0.04
Beta receptor blockers 37 (15) 27 (11) 0.26
Angiotensin 2 receptor
blockers
7 (3) 5 (2) 0.76
Calicium receptor blockers 22 (9) 12 (5) 0.07
Angiotensin-converting
enzyme inhibitors
14 (6%) 15 (6) 0.81
Statins 46 (19) 50 (20) 0.89
Nitrates 27 (11) 17 (7) 0.15
Any anti-anginal medicationa 64 (26) 42 (17) 0.01
Ex-test, exercise-stress testing; CTA, coronary computed tomography
angiography; CAD, coronary artery disease.
aAny anti-anginal medication: Beta receptor blockers, calcium receptor blockers,
or nitrates.
bTest not performed.
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0.004). The ex-test was inconclusive due to inadequate exercise
capacity in 7% of the patients, whereas CTA was inconclusive in
11% (P ¼ 0.14) due to motion artefacts (n ¼ 19), extensive coron-
ary calcification (n ¼ 8), or technical reasons (n ¼ 1).
Downstream test utilization
and treatment
Data on DTU previously have been reported.12 In brief, rates of
cardiac DTU were higher among patients in the ex-test compared
with the CTA group, 36 vs. 22% (P ¼ 0.001). The mode of cardiac
DTU according to the index test result is shown in Table 2. In
patients with an inconclusive test result DTU was applied in 93%
in the CTA vs. 33% in the ex-test group (P, 0.001). In patients
with a positive index test result, 34% in the ex-test group had sig-
nificant CAD at subsequent ICA (.50% narrowing of the lumen
in at least one vessel) compared with 65% in the CTA group
(P ¼ 0.02). No difference was observed in the frequency of coron-
ary revascularizations between the two groups. More patients in
the ex-test compared with the CTA group had anti-platelet
agents or any anti-anginal medication prescribed after the index
test. Additional testing was performed in 11 (4 chest X-rays, 7
chest CT scans, 1 mammography, 1 transoesophageal echcocardio-
graphy, 1 pulmonary scintigraphy, and 3 hepatic ultrasonographies)
out of 44 patients in the CTA group with one or more extra-
cardiac findings. Subsequently, in two patients malignancies were
diagnosed and treated (one breast lumpectomy with adjuvant
radiotherapy and one lung lobectomy).
Cardiac ambulatory contacts and
hospitalizations
No difference was observed between index test groups in the
proportion of patients with ≥1 ambulatory contacts on a suspicion
of angina, 27% in the ex-test group vs. 21% in the CTA group
(P ¼ 0.14), or in the proportion of patients with ≥1 downstream
CAD-related hospitalizations during follow-up, 6% in both groups.
Cost analysis
Mean (SD) total costs per patient after 1 year of follow-up were
higher in the ex-test group compared with the CTA group,
E1777 (3746) vs. E1510 (3974) (P ¼ 0.03). Including information
on extra-cardiac findings (DTU and treatment) increased mean
(SD) CTA-associated expenses to E1603 (4111) (P ¼ 0.05 when
comparing with costs in the ex-test group). The cumulated down-
stream costs during 12 months of follow-up are shown in Figure 1,
and the cumulated costs according to the index test result are
shown in Figure 2. Mean total costs per patient in relation to the
index test result and pre-test probability of CAD levels are
Figure 1 Cumulated total costs during 12 months of follow-up.
At 1 month (P ¼ 0.22), 6 months (P ¼ 0.16), 12
months(P ¼ 0.03). CTA, coronary computed tomography angiog-
raphy; ex-test, exercise-stress test.
Figure 2 Cumulated total costs for the two groups during 12
months of follow-up based upon positive (P ¼ 0.03), negative
(P ¼ 0.2), and inconclusive (P, 0.01) index test results. CTA,
coronary computed tomography angiography; ex-test,
exercise-stress test.
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presented in Table 3. Relative costs associated with cardiac DTU,
cardiovascular medication, coronary revascularizations, hospitaliza-
tions, and ambulatory visits, respectively, are illustrated in Figure 3.
Mean costs associated with DTU, cardiac ambulatory visits, cardio-
vascular medication, coronary revascularizations, and hospitalizations
at 12 months are shown in Table 4. The cumulated downstream test
costs (SD) per correctly identified patient with CAD (as evaluated by
ICA) were E9660 (16 658) in the ex-group compared with E5547
(11 872) in the CTA group.
Clinical follow-up
No patients from the two groups died within the follow-up period.
In the ex-test group three patients (all with a negative index test
result) suffered an acute myocardial infarction after 6, 8, and 12
months, respectively. Both patients with malignancy as detected
by the extra-cardiac analysis were free of disease after 12 months.
Radiation dose
The mean (SD) radiation dose of CTA, ICA, or MPI was 7.5 (3.6),
5.4 (2.9), and 7.5 (2.4) mSv, respectively. The total mean (SD) pro-
cedural radiation dose summating the dose from the index and
cardiac downstream diagnostic procedures was higher in the
CTA compared with the ex-test group, 9.0 (3.7) vs. 2.1 (3.7)
mSv (P, 0.001). The total mean (SD) radiation dose from down-
stream diagnostic procedures in the index test negative groups was
higher in the ex-test compared with the CTA group, 0.7 (2.2) vs.
0.05 (0.5) mSv (P, 0.001). In the index test positive groups, the
figures were 5.4 (3.9) for the ex-test vs. 4.9 (4.2) mSv for CTA
(P ¼ 0.55). In patients with an inconclusive index test result the
mean radiation from downstream diagnostic procedures was
higher in the CTA group compared with the ex-test group, 5.7
(4.1) vs. 2.8 (5.3) mSv (P ¼ 0.04).
Discussion
Diagnosis and treatment costs of CAD consume a large amount of
health-care resources.2 Cardiac imaging is a major contributor to
the rising health-care costs with a growth rate of 25% annually in
both the EU and the USA.13 Thus, the economic efficiency of
medical diagnostic strategies from the perspective of society is in-
creasingly important.
Guidelines on the management of stable angina from the Euro-
pean Society of Cardiology still recommend the ex-test as the ap-
propriate frontline non-invasive diagnostic test.3 Coronary CTA
has been proposed as an alternative non-invasive diagnostic modal-
ity in patients suspected of CAD, and numerous studies have
shown a notably high diagnostic accuracy of CTA in patients
with stable angina.4 Recent studies in patients suspected of CAD
indicate higher diagnostic performance of CTA in comparison
with ex-test.9 However, the higher diagnostic accuracy of CTA
compared with the ex-test may not change patient clinical and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Mean total costs according to the pre-test risk
of CAD and index test result
Variable Number (%) Mean total costs E (SD)
Test result
Ex-test, negative 164 (67) 665 (1782)a
CTA, negative 192 (77) 295 (802)
Ex-test, positive 65 (26) 4412 (5340)b
CTA, positive 31 (12) 8155 (8187)
Ex-test, inconclusive 18 (7) 2395 (5111)c
CTA, inconclusive 28 (11) 2481 (2242)
Pre-test risk
Ex-test, low 67 (27) 1138 (2908)d
CTA, low 70 (28) 1053 (3789)
Ex-test, intermediate 171 (69) 1879 (3740)e
CTA, intermediate 171 (68) 1562 (3987)
CAD, coronary artery disease; CTA, coronary computed tomography
angiography; ex-test, exercise-stress test; SD, standard deviation.
aP ¼ 0.2 when compared with CTA.
bP ¼ 0.03 when compared with CTA.
cP, 0.003 when compared with CTA.
dP ¼ 0.13 when compared with CTA.
eP ¼ 0.04 when compared with CTA.
Figure 3 Relative distribution of costs in the ex-test (A) and
CTA (B) groups at 12 months of follow-up. CTA, coronary com-
puted tomography angiography; DTU, downstream test utiliza-
tion; ex-test, exercise-stress test.
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cost outcomes unless the test result influences physician or patient
behaviour.
This study of symptomatic patients with a low-intermediate
pre-test likelihood of CAD indicates that the inferior diagnostic
performance of the ex-test relative to CTA is associated with an
overall reduction in downstream health-care costs by 14%. In
this study post-test cardiovascular medication-related costs were
22% higher in the ex-test compared with the CTA group. Non-
obstructive CAD may be revealed by CTA and result in a more se-
lective post-test medication strategy, e.g. patients at an intermedi-
ate pre-test risk of CAD may avoid cardiovascular preventive
medication in the event of a normal test result. When including in-
formation on extra-cardiac findings, the favourable cost profile of a
CTA vs. ex-test diagnostic strategy in this study was of borderline
significance only. The issue on extra-cardiac analysis in CTA is
somewhat controversial; hence it has been suggested that such a
strategy merely results in additional costs and morbidity without
a clear benefit on mortality.14 As opposed to the latter statement,
others including our institution believe in an ethical obligation to
review the entire CTA data set. However, important issues, i.e.
on long-term follow-up, life expectancy, quality of life, and job ab-
senteeism, were not included in this and other studies; thus the
cost-effectiveness of extra-cardiac analysis in CTA needs further
delineation in future studies.
The influence of CTA in the outpatient setting among patients
suspected of CAD on subsequent diagnostic testing, costs, and
clinical outcomes has been investigated in a few studies.15–17 In a
decision analytic model, Dewey et al.15 demonstrated a 17% reduc-
tion in costs per correctly identified patient with CAD (with a 10–
50% pre-test likelihood of CAD) by using CTA rather than the
ex-test or stress echocardiography studies. In an observational
study based on a private insurance claims database, Min et al.16
demonstrated a 12-month 26% reduction in total CAD-related
costs in individuals without known CAD (mean age, 57 years) fol-
lowing initial diagnostic testing by CTA rather than MPI. A recent
retrospective study by Shreibati et al.17 of Medicare beneficiaries
compared DTU and associated costs following stress testing and
CTA. At 6 months of follow-up, CAD-related costs were nearly
twice as high in patients diagnosed by CTA as in those in whom
the ex-test were performed. The average age in the study by
Shreibati et al. was 74 years (compared with 56 years in the
present study), and more patients had diabetes, hypertension,
and hyperlipidaemia compared with the present study cohort. As
the pre-test risk of anatomical CAD is positively associated with
the burden of coronary calcification, and inversely correlated to
the diagnostic specificity of CTA,18 subsequent increasing DTU
and costs must be anticipated in patients at a high risk of CAD.
Thus, the conflicting outcome between the study by Shreibati
et al. and the present one may at least partially be explained by
differences in the pre-test risk of CAD. The present study differs
from and is additive to the prior literature in that it, in a ‘real-world’
setting, examined the influence of patient-level differences (i.e. with
regard to the index diagnostic test outcome and the pre-test like-
lihood of CAD) on costs.
The cost efficiency of a diagnostic test necessitates in addition to
documentation of lower costs also equivalent or improved clinical
outcomes. In a recent study by Dedic et al.19 on CTA of anginal
patients, CTA was more efficient than the ex-test in predicting
subsequent serious cardiac events. In the aforementioned
studies by Min and Shreibati, however, there was no significant
difference in the frequency of serious cardiac events during
follow-up. In this study all adverse cardiac events during follow-
up occurred in the ex-test result negative group. However, the
incidence of cardiac events in this study was very low; hence
with regard to the safety of the two diagnostic strategies, conclu-
sions should be drawn with caution. The safety of frontline CTA
vs. ischaemia testing needs further investigation in future pro-
spective studies.
During the study period ischaemia testing was not performed
routinely prior to coronary revascularization in Denmark. Given
the limited accuracy of CTA in stenosis quantification20, it may
be speculated that a higher stenosis cut-point or additional detailed
lesion specific myocardial ischaemia testing such as MPI or fraction-
al flow reserve (FFR) may reduce the proportion of unnecessary
ICAs or coronary revascularizations following CTA and thus
costs. In concordance with the latter hypothesis is the fact that
an FFR-guided coronary revascularization strategy in patients
with multivessel disease seems to be cost-effective.21
Because of the radiation exposure associated to CTA, there is
much scrutiny on the increasing clinical use of this method.22
The radiation dose of the diagnostic modalities used in this study
was comparable with previous findings.22 Although the cumulated
associated effective radiation dose was consistently higher in
patients undergoing CTA compared with the ex-test, it should
be acknowledged that the ex-test in selected patients was asso-
ciated to a subsequent non-negligible radiation exposure. Aware-
ness of radiation use by physicians combined with technical
improvements, including ECG-triggered tube modulation for
spiral scan modes, prospectively triggered sequential scan proto-
cols, and the use of lower voltage in smaller sized patients have
brought down the daily average CTA radiation dose below
5 mSv.23 Moreover, high-pitch spiral CT with an effective dose
,1 mSv is increasingly used in mainstream practice.24
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Mean costs associated to DTU,
revascularization, cardiovascular medication,







DTU 704 (1214) 442 (946) 0.001
Revascularization 510 (2343) 649 (2846) 0.43
Cardiovascular
medication
207 (367) 170 (332) 0.03
Anti-anginal
medication
62 (109) 33 (69) 0.0001
Hospitalization 160 (760) 128 (638) 0.4
Ambulatory visits 196 (342) 120 (491) 0.046
CTA, coronary computed tomography angiography; DTU, downstream test
utilization; ex-test, exercise-stress test.
aData shown are means with standard deviations in parenthesis.
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The inherent limitations of the observational and retrospective
design of this study must be acknowledged. Although the two
study populations were identical with regard to baseline character-
istics (except for a more frequent use of nitrates in the ex-test
group) and the pre-test probability of CAD, a bias towards the
use of one rather than the other diagnostic strategy in certain
patient groups (e.g. physical incapacity or renal insufficiency)
cannot be excluded. The differences in DTU between groups
could reflect differences in operator skills rather than being test
related. However, all ex-test results were reviewed by experienced
cardiac clinicians before further action was taken. Moreover,
patient post-test management in this report reflects contemporary
clinical practice without the introduction of rigorous criteria on
post-test management. With respect to the study size, a dichotom-
ous definition of the test results was used. However, the latter
strategy provided a more valid comparison for estimating differ-
ences in downstream CAD-related costs and clinical outcomes.
Of note, a high proportion of patients in this study were, at the dis-
cretion of the treating physician, adjudicated as having ‘non-anginal’
chest pain. However, based on their total risk profile including sex
and age, most of the patients (70%) had a pre-test intermediate
risk of CAD, and thus fulfilled guidelines with regard to the rele-
vance of further diagnostic testing.3 This study was performed
from a health payer perspective, and indirect costs associated
with job absenteeism were not included. The outcomes of the
present study were restricted to 1 year. Overall, the findings in
the present study need confirmation in larger prospective trials.
The ongoing randomized PROspective Multicenter Imaging for
Evaluation of Chest Pain (PROMISE) trial investigates the influence
over 2-year follow-up of an initial anatomical diagnostic strategy
using CTA vs. initial stress testing on, e.g. medical costs and clinical
outcomes in patients suspected of CAD.25
Conclusion
In symptomatic patients with a low-intermediate probability of
CAD a frontline diagnostic strategy using CTA in comparison
with ex-test incurred lower costs. Future prospective studies are
needed in order to delineate further the consequences on costs
and safety of frontline CTA vs. ischaemia testing.
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